Clinical trial NCT01127451: Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma
Official title: A Phase II Open-Label, Multicenter Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Stage IIIC Melanoma
Stage IV Melanoma
Keywords: Neoplasms
Lead sponsor: Eisai Inc.
Sponsor class: INDUSTRY
Collaborators: name: PharmaBio Development Inc.
First posted: 2010-05-20
Enrollment: 75
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether participants with Stage IIIC and Stage IV Melanoma experience benefit when treated with Denileukin diftitox in two different dosing schedules.

Detailed description: This is a multicenter, open-label, dose/schedule and clinical efficacy study in participants with Stage IIIC and Stage IV melanoma.

Dose-Schedules: This is a schedule, dose, and pharmacodynamic study of Denileukin diftitox in participants with Stage IIIC and Stage IV melanoma. Two arms of 40 participants each were originally planned (see below) for a total of 80 participants. Participants were randomly assigned to 1 of 2 arms: 1. 12 mcg/kg/day on Days 1 through 4 of each 21-day treatment cycle, for a total of 4 cycles (12 weeks); 2. 12 mcg/kg/day on Days 1, 8, and 15 of each 21-day treatment cycle, for a total of 4 cycles (12 weeks). Participants will be evaluated for (clinical response, safety and tolerability, and pharmacodynamic measures of ONTAK activity. An optional substudy will be conducted that will involve collection of serial tumor biopsies at study entry and Day 84 in order to assess tissue pharmacodynamic markers of ONTAK activity (Treg depletion in tumor, appearance of melanoma antigen-specific CD8+lymphocytes, and other markers of mucosal immunity and inflammatory response).

Following an amendment, participants will be enrolled in Arm 1 only (expanded to a total of 55 participants) and Arm 2 was closed. According to the original design, if two responses or less were observed among 22 participants on either arm, that arm would be discontinued.

Participants experiencing clinical benefit (immune-related stable disease \[irSD\], immune-related partial response \[irPR\], or immune-related complete response \[irCR\] per irRC) after 4 cycles of treatment, may continue their denileukin diftitox treatment for up to 8 cycles.

Eligibility criteria: Inclusion Criteria Participants may be entered in the study only if they meet all of the following criteria.

1. Male or female participants greater than or equal to18 years of age;
2. Participants with histologically confirmed melanoma (Stage IIIC or Stage IV, American Joint Commission on Cancer);
3. Naive to prior systemic chemotherapy, targeted therapy (eg, BRAF), or immunotherapy (eg, interleukin-2 \[IL-2\] or interferon) for the treatment of melanoma, including any cytotoxic agents or IL-2 used for adjuvant therapy (adjuvant interferon is allowed). Prior granulocyte macrophage colony-stimulating factor (GM-CSF) is allowed;
4. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to 2;
5. Life expectancy greater than or equal to 3 months;
6. At least 1 site of radiographically measurable disease by immune-related response criteria (irRC);
7. Serum albumin greater than or equal to 3 g/dL;
8. Adequate hematologic, renal, and liver function as defined by laboratory values performed within 21 days prior to initiation of dosing:

   * Absolute neutrophil count (ANC) greater than or equal to 1.5 x 109/L;
   * Platelet count greater than or equal to 100 x 10\^9/L;
   * Hemoglobin greater than or equal to 9 g/dL;
   * Serum creatinine less than or equal 1.5 x upper limit of normal (ULN) or creatinine clearance greater than or equal to 50 mL/min;
   * Total serum bilirubin less than or equal to 1.5 x ULN;
   * Serum aspartate transaminase (AST/SGOT) or serum alanine transaminase (ALT/SGPT) less than or equal to 2.5 x ULN, and less than or equal to 5 x ULN if liver metastases are present.
9. Fertile males should use an effective method of contraception during treatment and for at least 3 months after completion of treatment, as directed by their physician;
10. Pre-menopausal females and females less than 2 years after the onset of menopause should have a negative pregnancy test at Screening. Pre-menopausal females must agree to use an acceptable method of birth control from the time of the negative pregnancy test up to 90 days after the last dose of study drug. Females of non-childbearing potential may be included if they are either surgically sterile or have been postmenopausal for greater than or equal to 1 year; Before study entry, written informed consent must be obtained from the participants prior to performing any study-related procedures.

Exclusion Criteria

Participants will not be entered in the study for any of the following:

1. Known central nervous system (CNS) lesions, except for asymptomatic non-progressing, treated brain metastases.

   Treated brain metastases are defined as having no evidence of progression or hemorrhage for 2 months, as ascertained by clinical examination and brain imaging (magnetic resonance imaging \[MRI\] or computerized tomography \[CT\]) during the Screening period (using the pretreatment brain image as Baseline). Treatment for brain metastases must have been completed at least 2 months prior to Day 1 of the first treatment cycle and may include whole brain radiotherapy, radiosurgery (Gamma Knife, LINAC, or equivalent), or a combination as deemed appropriate by the treating physician. Dexamethasone must be discontinued at least 4 weeks prior to Day 1. Participants with CNS metastases treated by neurosurgical resection or brain biopsy performed within 2 months prior to Day 1 will be excluded;
2. Carcinomatous meningitis;
3. Prior treatment with denileukin diftitox;
4. Known hypersensitivity to denileukin diftitox or any of its components: diphtheria toxin, IL-2, or excipients;
5. Prior surgery for melanoma less than 4 weeks before enrollment;
6. Other malignancy within 3 years of randomization, with the exception of adequately treated carcinoma in situ of the cervix or non-melanoma skin cancer, with no subsequent evidence of recurrence and/or malignancies diagnosed at a stage where definitive therapy results in near certain cures. The Medical Monitor must be consulted in such cases;
7. Currently receiving any other anticancer treatment for melanoma (including palliative radiotherapy);
8. Received treatment in another clinical study within the 4 weeks prior to commencing study treatment or participants who have not recovered from side effects of an investigational drug to Common Terminology Criteria for Adverse Events (CTCAE) Grade less than or equal to 1, except for alopecia;
9. Received radiotherapy for non-CNS disease within the 2 weeks prior to commencing study treatment or have not recovered from side effects of all radiation-related toxicities to Grade less than or equal to 1, except for alopecia;
10. Significant cardiovascular impairment (history of congestive heart failure New York Heart Association \[NYHA\] Grade greater than 2 \[see Appendix 5\], unstable angina, or myocardial infarction within the past 6 months, or serious cardiac arrhythmia);
11. Use of chronic systemic steroids (\>5 days) within 2 weeks of Day 1 of the first treatment cycle (replacement therapy for adrenal insufficiency is allowed);
12. Participants with an allograft requiring immunosuppression;
13. Known positive human immunodeficiency virus (HIV), known hepatitis B surface antigen, or hepatitis C positive;
14. Pregnant, breast-feeding, or refusing double barrier contraception, oral contraceptives, or avoidance of pregnancy measures; Have any other uncontrolled infection or medical condition that could interfere with the conduct of the study.

Primary outcomes:
measure: Percentage of Participants With Immune-related Overall Response Rate (irORR)
timeFrame: From the start of treatment up to 1 year 6 months
Secondary outcomes:
measure: Progression Free Survival (PFS)
timeFrame: From the start of treatment to the date of first documentation of irPD, or date of death, whichever occurred first up to 1 year 6 months
measure: Percentage of Participants With PFS at Month 6
timeFrame: Month 6
measure: Duration of Response
timeFrame: From date of the first demonstration of irCR or irPR until the date of first demonstration of PD, date of death, or withdrawal from study up to 1 year 6 months
measure: Overall Survival (OS)
timeFrame: From the date of randomization until the date of death up to 1 year 6 months
measure: Percentage of Participants With OS at 1 Year
timeFrame: From the date of randomization up to 1 year
measure: Change From Baseline in CD4+CD127-/loCD25+CD152- Cells Expression Pattern at Weeks 12
timeFrame: Baseline, Week 12
measure: Change From Baseline in CD4+CD127-/loCD25hiCD152- Cells Expression Pattern at Weeks 12
timeFrame: Baseline, Week 12
Other outcomes:
Locations:
city: Encinitas
country: United States
state: California
city: Los Angeles
country: United States
state: California
city: Washington
country: United States
state: District of Columbia
city: Chicago
country: United States
state: Illinois
city: Louisville
country: United States
state: Kentucky
city: Baltimore
country: United States
state: Maryland
city: Detroit
country: United States
state: Michigan
city: Lincoln
country: United States
state: Nebraska
city: Portland
country: United States
state: Oregon
city: Amarillo
country: United States
state: Texas
Study officials:
References: